HEALTHCARE

The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.

They have developed GluFormer, an AI model that can predict an individual’s future glucose levels and other health metrics based on past glucose monitoring data.

The reason for the closure is probably to do with problems at the US health insurance giant itself, which has seen its share price fall 15% in the past month.

80 medical students will be enrolled in the first four-year program, which will begin in February 2025. Annual fees are NIS 90,000.

Analysts are bullish on Teva, which is once again Israel's most valuable company, due to an improved US generics price environment and promising branded drug pipeline.

The Israeli pharmaceutical company beat the analysts and has again raised 2024 revenue guidance, this time to $16.1-16.5 billion.

The Dangoor Health-Tech Academy will foster collaboration between Israeli startups and Britain's National Health System, initially focusing on AI or automation-driven healthcare solutions.

The company has developed a device for the treatment of transcatheter tricuspid regurgitation (TR) using a revolutionary cross-caval technology.

Avraham Barak alleges that Teva's board and officers must have approved the criminal activity that led to the penalty.

Teva will pay a total of $450 million over six years to settle the cases.

The Yokneam based company has developed a nasal drug delivery system to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.

Nym has automated the entire US healthcare medical coding process to deliver a faster, more cost-effective solution that outperforms traditional manual coding.

The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient.

Under the settlement, Teva's insurance company, which as far as is known is not Israeli, will pay the pharmaceutical company $40 million to fully close all potential claims.

Epitomee's product expands in the stomach, giving a sense of satiety. The big challenge now will be marketing.

The Israeli company has developed a device for the treatment of degenerative disc diseaseõ

Level Ex founder and CEO Sam Glassenberg tells "Globes" about the growing industry of medical video games and apps to train and improve the performance of doctors.

Chemomab Therapeutics is developing a treatment for rare liver scarring disease PSC.

V-Wave’s shunt is an implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure.

Ultimately the Israeli company’s platform was not distinct enough from other nutritional menus.

Teva CEO: We are also showing significant progress in on our late-stage innovative pipeline.

The company is investing in a production plant in Tirat Hacarmel, using innovative aeroponic cultivation technology.

The company has developed a miniature heart pump that can be inserted into the body through minimally invasive surgery.

Six of the world’s top 10 pharma companies use CytoReason’s technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas.

The sale to Edwards Lifesciences vindicates Innovalve's solution for the most common, and most challenging, heart valve disorder, and also Sheba Hospital's innovation model.

Swedish company Mölnlycke Health Care, an international leader in the field of treating wounds, led the private placement.

Sources estimate that Edwards will pay more than $300 million for Innovalve's trans-catheter mitral valve replacement device.

The Israeli businessman's long term aim is to build Phcann in the medical cannabis market in Europe including the UK, as well as in Australia.

The Israeli company has developed a pineapple-plant based product for treatment of burns and wounds.

Alcon will make an immediate payment of $81 million and a further $385 million in milestone payments, according to the product's success on the market.